Christopher Furman - 11 Nov 2022 Form 3/A - Amendment Insider Report for Vitro Biopharma, Inc.

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Furman
Issuer symbol
N/A
Transactions as of
11 Nov 2022
Net transactions value
$0
Form type
3/A - Amendment
Filing time
30 Jun 2023, 20:35:36 UTC
Date Of Original Report
14 Nov 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding Employee Stock Option (Right to Buy) 11 Nov 2022 Common Stock 5,000,000 $1.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option became exercisable as to 1,000,000 shares on July 6, 2022, and will become exercisable as to (i) 1,000,000 shares on July 6, 2023, (ii) 1,000,000 shares on July 6, 2024, (iii) 1,000,000 shares on July 6, 2025, and (iv) 1,000,000 shares on July 6, 2026.

Remarks:

This amendment is filed solely to reflect the proper exercise price for the stock options granted.